[go: up one dir, main page]

MX2018015508A - Sales farmaceuticas de n-(2-(2-dimetilamino)etoxi)-4-metoxi-5-((4- (1-metil-ih-indol-3-il)pirimidin-2-il)amino)fenil)acrilamida y formas cristalinas de las mismas. - Google Patents

Sales farmaceuticas de n-(2-(2-dimetilamino)etoxi)-4-metoxi-5-((4- (1-metil-ih-indol-3-il)pirimidin-2-il)amino)fenil)acrilamida y formas cristalinas de las mismas.

Info

Publication number
MX2018015508A
MX2018015508A MX2018015508A MX2018015508A MX2018015508A MX 2018015508 A MX2018015508 A MX 2018015508A MX 2018015508 A MX2018015508 A MX 2018015508A MX 2018015508 A MX2018015508 A MX 2018015508A MX 2018015508 A MX2018015508 A MX 2018015508A
Authority
MX
Mexico
Prior art keywords
indol
pyrimidin
dimethylamino
ethoxy
methoxy
Prior art date
Application number
MX2018015508A
Other languages
English (en)
Inventor
Nicholas Greco Michael
John Costanzo Michael
Peng Jirong
Lynn Wilde Victoria
Zhang Don
Alan Green Michael
Original Assignee
Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Inc filed Critical Beta Pharma Inc
Publication of MX2018015508A publication Critical patent/MX2018015508A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se divulga N-(2-(2-(dimetilamino)etoxi)-4-metoxi-5-((4-(1-metil-1H -indol-3-il)pirimidin-2-il)amino)fenil) acrilamida (1) y sus sales farmacéuticamente aceptables y composiciones de las mismas para el tratamiento o la prevención de enfermedades o condiciones médicas a través de formas mutadas del receptor del factor de crecimiento epidérmico (EGFR), tales como diversos cánceres.
MX2018015508A 2016-06-17 2017-06-16 Sales farmaceuticas de n-(2-(2-dimetilamino)etoxi)-4-metoxi-5-((4- (1-metil-ih-indol-3-il)pirimidin-2-il)amino)fenil)acrilamida y formas cristalinas de las mismas. MX2018015508A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662351749P 2016-06-17 2016-06-17
PCT/US2017/037872 WO2017218892A1 (en) 2016-06-17 2017-06-16 Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof

Publications (1)

Publication Number Publication Date
MX2018015508A true MX2018015508A (es) 2019-04-11

Family

ID=60664309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015508A MX2018015508A (es) 2016-06-17 2017-06-16 Sales farmaceuticas de n-(2-(2-dimetilamino)etoxi)-4-metoxi-5-((4- (1-metil-ih-indol-3-il)pirimidin-2-il)amino)fenil)acrilamida y formas cristalinas de las mismas.

Country Status (17)

Country Link
US (1) US10844045B2 (es)
EP (1) EP3471730B1 (es)
JP (1) JP6928964B2 (es)
KR (1) KR20190018494A (es)
CN (1) CN109937043A (es)
AU (1) AU2017285448B2 (es)
BR (1) BR112018075823A2 (es)
CA (1) CA3027732A1 (es)
CO (1) CO2018013416A2 (es)
EA (1) EA201892661A1 (es)
IL (1) IL263619A (es)
MX (1) MX2018015508A (es)
PH (1) PH12018502668A1 (es)
SG (1) SG11201810976TA (es)
TW (1) TW201800404A (es)
WO (1) WO2017218892A1 (es)
ZA (1) ZA201808234B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201911859QA (en) * 2017-06-16 2020-01-30 Beta Pharma Inc Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
CN110898026A (zh) * 2019-12-11 2020-03-24 倍而达药业（苏州）有限公司 包含bpi-7711的药用组合物及其制备方法
CN111100117B (zh) * 2019-12-18 2021-02-19 上海倍而达药业有限公司 氨基嘧啶类化合物甲磺酸盐的晶型a及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2736895B1 (en) 2011-07-27 2016-01-06 Astrazeneca AB 2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
DE102011115849B3 (de) 2011-10-13 2012-05-10 Thomas Magnete Gmbh Vorrichtung zum Dosieren und Zerstäuben von Flüssigkeiten mit vorgespanntem Dämpfer
HUE042390T2 (hu) 2014-06-19 2019-06-28 Ariad Pharma Inc Heteroaril vegyületek kinázgátlásra
CN105315285B (zh) 2014-07-25 2017-12-08 上海海雁医药科技有限公司 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
CN113121575A (zh) 2014-08-25 2021-07-16 四川海思科制药有限公司 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途
JP6456086B2 (ja) * 2014-09-25 2019-01-23 キヤノン株式会社 投影型画像表示装置及びその制御方法並びにプロジェクタ及びその制御方法
CN111170998B (zh) * 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
MY183474A (en) 2014-12-10 2021-02-19 Oji Holdings Corp Absorbent article
AU2015360360B2 (en) 2014-12-11 2020-06-25 Beta Pharma (Shanghai) Co., Ltd. Substituted 2-anilinopyrimidine derivatives as EGFR modulators
CN104961731A (zh) 2015-02-05 2015-10-07 苏州晶云药物科技有限公司 一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法
CN104910049B (zh) 2015-06-16 2016-06-29 苏州明锐医药科技有限公司 Azd9291中间体及其制备方法
TW201740951A (zh) 2016-05-11 2017-12-01 貝達醫藥公司 做為用於治療腦癌的治療劑之2-苯胺嘧啶

Also Published As

Publication number Publication date
JP2019518062A (ja) 2019-06-27
EP3471730B1 (en) 2021-10-20
SG11201810976TA (en) 2019-01-30
IL263619A (en) 2019-01-31
EP3471730A1 (en) 2019-04-24
TW201800404A (zh) 2018-01-01
AU2017285448A1 (en) 2019-01-03
US20190233399A1 (en) 2019-08-01
CN109937043A (zh) 2019-06-25
EP3471730A4 (en) 2019-11-27
BR112018075823A2 (pt) 2019-03-26
CO2018013416A2 (es) 2019-01-18
EA201892661A1 (ru) 2019-07-31
ZA201808234B (en) 2019-11-27
PH12018502668A1 (en) 2019-10-07
KR20190018494A (ko) 2019-02-22
WO2017218892A1 (en) 2017-12-21
AU2017285448B2 (en) 2021-02-04
CA3027732A1 (en) 2017-12-21
JP6928964B2 (ja) 2021-09-01
US10844045B2 (en) 2020-11-24

Similar Documents

Publication Publication Date Title
PH12019502830A1 (en) Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
CY1124848T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν azd9291
CY1124359T1 (el) Ενωσεις και συνθεσεις για ρυθμιση δραστικοτητων κινασης μεταλλακτικου egfr
MX380928B (es) Inhibidores de kras g12c.
EA201992128A1 (ru) Конденсированные имидазопиперидиновые ингибиторы jak
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
MX387984B (es) Inhibidor del egfr y preparación y aplicación del mismo.
TR201903322T4 (tr) Kinaz inhibisyonu için heteroaril bileşikleri.
MX379459B (es) Inhibidores de bromodominios.
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
WO2016109217A3 (en) Btk inhibitors
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
TN2017000158A1 (en) Carbazole derivatives
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
WO2014106800A3 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
NZ752587A (en) Lsd1 inhibitors and medical uses thereof
PH12018502668A1 (en) Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof
ZA202006071B (en) Antiproliferation compounds and uses thereof
CY1124733T1 (el) Antimykhtiaσιko φαρμακευτικο σκευασμα
MX2024006771A (es) Forma cristalina de n-(2-cloro-3-((5-cloro-3-metil-4-oxo-3,4-dihid roquinazolin-6-il)amino)-4-fluorofenil)-3-fluoroazetidina-1-sulfo namida.
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
CN109689657A (zh) 氘代3-(4,5-取代氨基嘧啶)苯基衍生物及其应用
RU2007147957A (ru) Комбинация производных пиримидиламинобензамида и иматиниба для лечения или профилактики пролиферативных заболеваний
NZ748942A (en) Pyrazolylaminobenzimidazole derivatives as jak inhibitors